These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29296917)

  • 1. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
    Merryman RW; Armand P; Wright KT; Rodig SJ
    Blood Adv; 2017 Dec; 1(26):2643-2654. PubMed ID: 29296917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
    Lin N; Song Y; Zhu J
    Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
    Hu B; Jacobs R; Ghosh N
    Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.
    De Goycoechea D; Stalder G; Martins F; Duchosal MA
    J Oncol; 2019; 2019():9513701. PubMed ID: 31205470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?
    Jeong AR; Ball ED; Goodman AM
    Clin Med Insights Oncol; 2020; 14():1179554920976366. PubMed ID: 33447123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review.
    Perdikis-Prati S; Sheikh S; Bouroumeau A; Lang N
    Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.
    Katsuya H; Suzumiya J; Kimura S
    Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Tang G; Fan G; Xu J
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
    Tobin JWD; Bednarska K; Campbell A; Keane C
    Cells; 2021 May; 10(5):. PubMed ID: 34068762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas.
    Ribatti D; Cazzato G; Tamma R; Annese T; Ingravallo G; Specchia G
    Front Oncol; 2024; 14():1420920. PubMed ID: 39091917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.
    Veldman J; Visser L; Berg AVD; Diepstra A
    Cancer Treat Rev; 2020 Jan; 82():101931. PubMed ID: 31756590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma.
    Khurana A; Armand P; Ansell SM
    Leuk Lymphoma; 2020 May; 61(5):1063-1074. PubMed ID: 31914840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
    Allen PB; Gordon LI
    Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PD-1 blockade therapy in lymphoid malignancies].
    Nishikori M; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.
    Duffield AS; Ascierto ML; Anders RA; Taube JM; Meeker AK; Chen S; McMiller TL; Phillips NA; Xu H; Ogurtsova A; Berger AE; Pardoll DM; Topalian SL; Ambinder RF
    Blood Adv; 2017 Jul; 1(17):1324-1334. PubMed ID: 29296775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on checkpoint blockade therapy for lymphoma.
    Kline J; Bishop MR
    J Immunother Cancer; 2015; 3():33. PubMed ID: 26199729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
    Wienand K; Chapuy B; Stewart C; Dunford AJ; Wu D; Kim J; Kamburov A; Wood TR; Cader FZ; Ducar MD; Thorner AR; Nag A; Heubeck AT; Buonopane MJ; Redd RA; Bojarczuk K; Lawton LN; Armand P; Rodig SJ; Fromm JR; Getz G; Shipp MA
    Blood Adv; 2019 Dec; 3(23):4065-4080. PubMed ID: 31816062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.